Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Low gradient and LV Dysfunction: TAVI or not?

Original Title: Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement.

Reference: Baron SJ et al. J Am Coll Cardiol. 2016;67:2349-2358.

 

Stethoscope with heart on suit background, close-up

Low aortic valve gradient and left ventricular dysfunction are frequent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVI) but only low aortic valve gradient is associated with worse prognosis at one year, according to the recently published Transcatheter Valve Therapy (TVT) registry.

These findings suggest that low aortic valve gradient in patients with aortic stenosis is an important factor to consider when assessing risk/benefit ratio, since it has an important impact prognosis compared to low ejection fraction, which doesn’t seem as important.

Aside from this, neither of these two factors, separately or combined, seems to be enough not to prescribe TAVI.

Patients with severe LV dysfunction and low aortic valve gradient have 33% 1 year mortality, as observed in patients with this characteristics submitted to medical treatment in the PARTNER B.

This trial assessed data from 11292 patients undergoing TAVI between 2011 and 2014 included in the TVT registry (Society of Thoracic Surgeons/American College of Cardiology).

Patients were divided in three groups according to ventricular dysfunction:

  • Severe dysfunction (<30%).
  • Mild to moderate dysfunction (30-50%).
  • Preserved (>50%).

Aortic valve gradient was considered low (<40 mmHg) or high (≥40 mmHg). Mean gradient was lower in patient with severe LV dysfunction. LV function was worse in patients with low gradient.

Outcomes:

  • Patents with LV dysfunction and low aortic valve gradient had more prolonged post procedure hospitalization and had higher in hospital mortality. AT one year follow up, both factors were associated with higher risk of death and heart failure.
  • Patients with preserved LV dysfunction and high gradient had better prognosis at one year (23.6% mortality and 11.2% heart failure) compared to those with LV dysfunction and low gradient, with much worse prognosis (33.1% y 23.6%, respectively).
  • In multivariable analyzis, only low gradient was associated to higher mortality (HR 1.21; CI 95% 1.11-1.32) and recurrent heart failure (HR 1.52; CI 95% 1.36-1.69). These events and LV dysfunction were not significantly associated.

Editorial Comment

The greatest strength of this study was the big number of real world patients, and the limitation, that there was no “core lab” to adjudicate events, echocardiographic data was limited and of course there was no control group.

The information on aortic valve gradient, valve area, flow and ejection fraction, should be systematically integrated when stratifying severe aortic stenosis patients.

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...